BOSTON and SEOUL, Korea, June 6, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON" or "Company") announced today that the company has successfully completed the GLP toxicology studies of BAL200. The ...
It aims to promote strategic collaborations in global while also highlights its many innovative advances and successful scientific ventures. BOSTON and SEOUL, South Korea, May 9, 2022 /PRNewswire/ -- ...
BOSTON and SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- More than 1,200 reported cases of CRE (Carbapenem-Resistant Enterobacteriaceae) infections have been reported in the In-cheon region of ...
iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The ...
iNtRON stated that following the proprietary development of the Robot Bacteriophage 2 nd generation technology, additional in-vitro evolution technology was applied. The Company previously secured the ...
Intron Technology’s 01760 2022 result was driven by strong growth in revenue from electric vehicles and automated vehicles, with consolidated revenue up 52% and net profit up 107%. Together, these two ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results